<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164782">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01853397</url>
  </required_header>
  <id_info>
    <org_study_id>13-137-LP-H</org_study_id>
    <nct_id>NCT01853397</nct_id>
  </id_info>
  <brief_title>Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment Method</brief_title>
  <official_title>An Evaluation of the Safety and Effectiveness of Treatment of Adipose Tissue With the Liposonix System (Model 2) Using a New Treatment Method</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solta Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solta Medical</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, and tolerability of treatment
      with the Liposonix System (Model 2)using a single pass technique.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy of the single pass method through reduction from baseline in waist circumference 12 weeks after treatment as assessed by independent blinded evaluators and comparability of waist circumference reduction 12 weeks after treatment between active (single pass) and control (grid repeat) treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>4 weeks, 8 weeks, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy of the single pass method through reduction from baseline in waist circumference measured at 4, 8, and 16 weeks after treatment as assessed by independent blinded evaluators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment of treatment</measure>
    <time_frame>4, 8, 12, and 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Study Investigator will assess improvement in the treatment area(s) using the Global Aesthetic Improvement Scale (GAIS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Treatment</measure>
    <time_frame>4, 8, 12, and 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject will assess improvement in the treatment area(s) using the Global Aesthetic Improvement Scale (GAIS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction with treatment</measure>
    <time_frame>4, 8, 12, and 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects will rate their satisfaction with treatment results using a 5-point Likert Satisfaction Scale</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Evaluate the Safety, Efficacy, and Tolerability of Treatment With the</condition>
  <condition>Liposonix System Using a Single Pass Technique</condition>
  <arm_group>
    <arm_group_label>Treatment at level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment at level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment at level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with 3 passes at 60 J/cm2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Liposonix System (Model 2)</intervention_name>
    <arm_group_label>Treatment at level 1</arm_group_label>
    <arm_group_label>Treatment at level 2</arm_group_label>
    <arm_group_label>Treatment at level 3</arm_group_label>
    <arm_group_label>Treatment with 3 passes at 60 J/cm2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 65 years of age

          -  Body Mass Index of ≤30 kg/m2

          -  Thickness of subcutaneous adipose tissue in the anticipated treatment area of ≥ 2.3
             cm

          -  Subjects must agree to not alter their normal and regular diet or exercise routines
             during the course of the study

          -  Subject must understand the nature of the study and sign an IRB approved Informed
             Consent

        Exclusion Criteria:

          -  Subject is pregnant

          -  Subject is diagnosed with coagulation disorders or are receiving anticoagulant
             therapy or medications or dietary supplements which impede coagulation or platelet
             aggregation

          -  Subject has diabetes or cardiovascular disease

          -  Subject has had prior aesthetic procedures to the region to be treated

          -  Subject has had previous open or laparoscopic surgery in the anticipated treatment
             area

          -  Subject is on prescription or over the counter weight reduction medication or
             programs, or had weight reduction procedures

          -  Subjects undergoing chronic steroid or immunosuppressive therapy

          -  Subject has cardiac pacemakers or any implantable electrical device

          -  Subject has a History of cancer

          -  Subject has sensory loss or dysesthesia in the area to be treated

          -  Subjects who are unable, or lack the capacity, to self consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Solta Medical Aesthetic Center</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>94545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewell Plastic Surgery Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>May 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
